Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of GSK249320 in Stroke Patients
NCT00833989Phase 2Completed
- Sponsor
- GSK
- Start
- Jul 2009
- Primary completion
- Jan 2011
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of refanezumab in stroke, sponsored by GSK. Started Jul 2009; status: completed.
02
Drugs
refanezumab
03
Conditions
stroke
Beyond the preview
Go deeper on NCT00833989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00833989.